BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
See today's BioWorld
Home
» XBiotech's 'True Human' Antibody Xilonix Hits the Spot for Cachexia
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
XBiotech's 'True Human' Antibody Xilonix Hits the Spot for Cachexia
Oct. 5, 2012
By
Anette Breindl
No Comments
Austin-based XBiotech Inc. is launching its first Phase III trial, for its antibody Xilonix (MABp1), after announcing Wednesday that the monoclonal antibody received fast-track designation by the FDA.
BioWorld